Padagis Achieves A US First With Budesonide Foam Launch
Rival To Uceris Rectal Foam Benefits From 180 Days Of CGT Exclusivity
Executive Summary
Padagis has launched budesonide 2mg rectal foam, the first US generic version of Uceris, with 180 days of competitive generic therapy exclusivity.
You may also be interested in...
ANI Aims For CGT Top Spot With Two New Launches
ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.
Who's Hired? Padagis Gets New Leadership
Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.
Padagis Introduces Fresh Narcan Rival In US
Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.